Maine lawmakers are currently examining two bills aimed at implementing mandatory testing for medical cannabis products. This move comes as a response to the absence of testing requirements in Maine’s medical cannabis program, which sets it apart from over 30 other states that have established such regulations.
Currently, cannabis sold for recreational use in Maine undergoes testing for harmful substances like pesticides, mold, and heavy metals. However, products sold through the medical cannabis program do not face the same scrutiny, a situation that has raised concerns among health advocates.
Matt Wellington, associate director of the Maine Public Health Association, emphasized the importance of ensuring that medical cannabis products are safe for patients. “These products are used by folks across Maine to manage health conditions,” Wellington stated. “They deserve assurance that they are not contaminated with substances that could actually harm their health.”
Data from the Maine Office of Cannabis Policy indicates that in 2023, 42% of medical cannabis samples tested positive for at least one contaminant that would have failed adult-use standards. This statistic underscores the need for stricter regulations in the medical sector.
Despite the push for testing requirements, some medical cannabis growers and patients have voiced concerns about the potential financial burden. Opponents argue that mandatory testing could increase costs for small farmers, many of whom already operate with minimal profit margins. Derek Shirley, a medical cannabis patient actively involved in legislative discussions, noted that the medical cannabis industry has seen a significant decline, with the number of registered caregivers dropping from over 3,000 to just 1,600. “These regulations would put a lot of farmers out of business,” Shirley warned, asserting that the regulations could threaten the livelihoods of many small operators.
Maine’s cannabis market includes two distinct systems: a medical program with more than 1,600 registered caregivers serving over 100,000 patients annually, and a recreational program that generated nearly $244 million in sales in 2024 through 4.5 million transactions. In 2025, the adult-use sector has reported approximately $56 million in sales thus far.
One of the bills under consideration, LD 104, would require mandatory testing of medical cannabis for contaminants such as pesticides and heavy metals. Another bill, LD 1847, aims to introduce additional regulations, including tracking and tracing requirements and capping the THC content in edible medical cannabis products. This bill also proposes a study group to explore youth cannabis use and suggests reallocating some tax revenue from adult cannabis sales to public health initiatives.
Representative Marc Malon, who sponsors LD 104 at the request of the state’s cannabis policy office, expressed strong support for the proposed testing requirements. He pointed out that Maine is the only state among those with medical cannabis programs that does not mandate testing, emphasizing the need for higher standards in medical cannabis. “The word medical means something; it connotes a higher purpose and quality,” Malon stated.
The legislative committee will review these bills in an upcoming work session, with discussions likely to continue as lawmakers weigh the benefits of patient safety against the potential impact on small cannabis businesses.
English 
Spanish 
German 
Czech